A. A BTK inhibitor (ibrutinib or acalabrutinib) B. Venetoclax-based therapy C. FCR or BR D. Either a BTK inhibitor or venetoclax-based therapy would be appropriate

A. If resolved within 24–48 hours of last dose, resume same dose B. If requires more than 48 hours to resolve, resume at reduced dose C. Ensure adequate oral and/or IV hydration D. All are correct interventions

A. Switch to a more selective BTK inhibitor to minimize off-target effects, such as hypertension B. Initiate an additional antihypertensive agent, such as metoprolol, to control patient's noted hypertension C. Hold ibrutinib for 7 days and then resume at the same dose D. A or B

A. Switch therapies, as headache is unlikely to improve with continued therapy B. Recommend acetaminophen and caffeine, and counsel that headaches are often transient and resolve within 4–8 weeks C. Recommend NSAID therapy, as it is the safest and most effective treatment for BTK inhibitor–induced headache

A. Decrease the ibrutinib dose B. Switch to another BTK inhibitor C. Given the presence of the BTK mutation, patient should not receive BTK inhibitor therapy; switch patient to a different drug class